MedPath

Jord BioScience Raises Series B Funding to Advance Agricultural Microbial Solutions

• Jord BioScience has secured Series B funding led by Silver Blue LLC, with participation from Discovery Capital Funding and other investors to accelerate microbial technology development for agriculture.

• The company leverages a proprietary bank of over 6,500 microbial isolates collected globally to enhance crop performance in major agricultural products including corn, soybeans, canola, and wheat.

• Under CEO Dr. Keri Carstens' leadership, Jord BioScience aims to scale operations and fast-track biological solutions development through partnerships with leading agribusinesses.

Minneapolis-based Jord BioScience has successfully closed its Series B funding round, marking a significant advancement in the development of innovative microbial solutions for agricultural applications. The funding, led by Maryland-based agrifoodtech investor Silver Blue LLC, includes participation from Discovery Capital Funding, Minnesota's Small Business Credit Initiative (SSBCI) Direct Investment, and existing investors.

Strategic Investment to Scale Microbial Innovation

The investment will accelerate Jord BioScience's efforts to develop and commercialize next-generation crop inputs through their advanced microbial technologies. The company's approach combines deep scientific expertise with practical agricultural applications, positioning them at the forefront of biological innovation in farming.
"This funding round marks a significant milestone for Jord BioScience, validating our partnership approach and the true potential of our microbial solutions to transform agriculture," stated Dr. Keri Carstens, President and CEO of Jord BioScience. "With this investment, we're poised to scale our operations to help biologicals and crop inputs companies accelerate product discovery and innovation for farmers worldwide."

Comprehensive Microbial Platform

At the heart of Jord BioScience's technology is their extensive microbial bank, comprising over 6,500 isolates collected from diverse global soils. This comprehensive collection, developed under the guidance of Chief Science Officer Dr. Linda Kinkel's 30 years of expertise, represents microorganisms from various geographies, habitats, and soil chemistries.
The company's microbial solutions are designed to enhance, protect, or promote distinct modes of action in major agricultural crops, including:
  • Corn
  • Soybeans
  • Canola
  • Wheat
  • Various specialty crops

Industry Impact and Future Outlook

Francis Goelet, Director at Silver Blue LLC, emphasized the unique position of Jord BioScience in the biological innovation landscape: "While biological innovation continues to evolve, Jord BioScience stands out by offering a fast and cost-effective approach to product differentiation, life cycle management, and revenue generation for agricultural companies."
The investment comes at a crucial time when agricultural producers face increasing pressure to enhance food production while managing financial and environmental constraints. Jord BioScience's technology aims to address these challenges by improving the consistency and performance of biological solutions in agriculture.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Abcuro Secures $200M Series C to Advance Phase II/III Trial for Rare Muscle Disease Treatment

Abcuro raises $200 million in Series C financing to support Phase II/III MUSCLE clinical trial of ulviprubart, targeting inclusion body myositis through KLRG1 inhibition.
The funding will facilitate Abcuro's preparation for a Biologics License Application (BLA) submission and subsequent commercial launch of their novel antibody therapy.

Abcuro Secures $200M Series C Funding to Advance Novel IBM Treatment Ulviprubart

Abcuro has raised $200 million in Series C financing led by NEA to advance ulviprubart, a first-in-class monoclonal antibody treatment for inclusion body myositis (IBM).
The funding will support completion of the Phase 2/3 MUSCLE trial for ulviprubart, preparation for BLA filing, and commercial launch activities, with initial data expected in early 2026.

Normunity Secures $75 Million to Advance Solid Tumor-Targeting T-Cell Engager NRM-823

Normunity has raised $75 million in Series B funding to advance its lead program, NRM-823, a T-cell engager targeting solid tumors, into Phase 1 trials.
NRM-823, a first-in-class T-cell engager, binds to a highly specific tumor-associated target expressed across multiple solid tumor types.

XyloCor Therapeutics Secures $67.5 Million to Advance Gene Therapy for Cardiovascular Disease

XyloCor Therapeutics has raised $67.5 million in a Series B financing round led by Jeito Capital to advance its cardiovascular gene therapy program.
The funding will support two Phase 2 clinical trials of XyloCor's lead candidate, XC001, for refractory angina and as an adjunctive treatment to CABG.

FibroBiologics Secures $25M Equity Purchase Agreement to Advance Clinical Programs in Multiple Diseases

FibroBiologics has entered into a $25 million Standby Equity Purchase Agreement with Yorkville Advisors Global, securing immediate access to $15 million in three tranches. The funding will support the company's first-in-human trial for diabetic foot ulcers, psoriasis program development, and advancement of multiple therapeutic programs including multiple sclerosis and cancer treatments.

AusperBio Secures $73 Million to Advance Chronic Hepatitis B Therapy

AusperBio has successfully completed a $73 million Series B financing round to advance its lead therapy, AHB-137, for a functional cure for chronic hepatitis B.
The funding will support Phase 2 clinical trials of AHB-137 in China and globally, along with the development of commercial-scale manufacturing processes.

Genespire Secures $52 Million to Advance Gene Therapy for Methylmalonic Acidemia

Genespire has raised $52 million in a Series B financing round to advance its gene therapy program for Methylmalonic Acidemia (MMA).
The funding will support the development of GENE202, an off-the-shelf gene therapy, through a Phase I/II clinical trial.

Bambusa Therapeutics Secures $15 Million Seed Funding for Bispecific Antibody Development

Bambusa Therapeutics has successfully closed a Series Seed financing round, raising approximately $15 million to advance its bispecific antibody programs.
The funding will support the development of Bambusa's pipeline of bispecific antibodies, aimed at treating immunological and inflammatory disorders, towards Phase I clinical studies.

N-Power Medicine Secures Series B Funding to Enhance Oncology Clinical Trials Access

N-Power Medicine has announced the initial close of its Series B funding round, raising its total funding to $72 Million. The funding, led by Merck Global Health Innovation Fund, aims to expand the company's network of oncology clinics and biopharmaceutical collaborations, leveraging its unique platform for integrating clinical research into everyday patient care.

ByHeart Secures $90M Series B Funding After Successful Infant Formula Clinical Trial

ByHeart secured $90 million in Series B funding to launch its infant formula and advance its pipeline of mom and baby products.
The company's clinical trial with 311 babies met all endpoints, a key step for FDA submission and market entry.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy